DelveInsight’s ‘AL Amyloidosis – Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the AL amyloidosis, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The AL Amyloidosis market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted AL amyloidosis symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current AL amyloidosis symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
AL Amyloidosis Overview
Amyloidosis refers to a group of complex diseases caused by protein misfolding and aggregation into highly ordered amyloid fibrils that deposit in tissues, resulting in progressive organ damage. A cross-β-sheet quaternary structure characterizes these amyloid fibrils. It is typically found in individuals with monoclonal gammopathy.
AL amyloidosis is characterized by the proliferation of clonal plasma cells. It causes the increased production of immunoglobulin light chains to become misfolded and aggregate into amyloid fibrils, leading to organ damage. As the amyloid builds up in an organ, nerve, or tissue, it gradually causes damage and affects their function. Each amyloidosis patient has a different pattern of amyloid deposition in their body. It often affects more than one organ, except the brain.
Changes in proteins, turning them into amyloids, occur because of gene mutations in DNA within cells. As amyloids are insoluble, they deposit in organs and tissues, causing amyloidosis; these amyloid proteins accumulate mainly in the tissue space between cells. The Washington University Amyloid Center is among the few places in the US capable of treating this rare condition. Their experienced team offers leading-edge treatments to help improve the patient’s symptoms.
It covers the details of conventional and current medical therapies and diagnosis available in the AL amyloidosis market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
DelveInsight’s AL amyloidosis market report gives a thorough understanding of AL amyloidosis symptoms by including details such as disease definition, symptoms, causes, physiology, and diagnosis. It also provides the symptoms, treatment algorithms, and treatment guidelines for AL Amyloidosis symptoms in the US, Europe, and Japan.
Early diagnosis remains vital for improving treatment efficacy and overall survival. Earlier diagnosis and better treatment options have reduced early deaths and improved survival in the past few years. When amyloid deposits are detected in biopsy samples, accurate identification of the precursor protein is crucial to guide treatment. This is feasible using immunohistochemistry, in highly specialized laboratories, and using immune-electron microscopy. The mass spectrometry-based analysis of the amyloid-containing tissues is now considered the best approach, with a reported sensitivity of 88% and specificity of 96% higher than immunochemical techniques. Also, the mass-spectrometry-based analysis does not require a large panel of antisera to identify non-AL amyloidosis.
Treatment for AL amyloidosis is tailored to the patient with their health in mind. The type of treatment is based on disease progression and the seriousness of the patient’s organ, tissue, and nerve involvement. Supportive treatment is helpful for various symptoms, including cardiac and kidney problems, and can change many people’s quality of life.
The AL Amyloidosis symptoms epidemiology division provides insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The incident cases of AL Amyloidosis in the 7MM will increase during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical and forecasted AL Amyloidosis symptoms epidemiology segmented as the total incident cases of AL amyloidosis, Gender-specific cases of AL amyloidosis, and age-specific cases of AL amyloidosis. The report includes the incident scenario of AL amyloidosis symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
The epidemiology segment also provides the AL Amyloidosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total incident cases of AL Amyloidosis associated in 7MM countries were 8,550 in 2017.
The drug chapter segment of the AL Amyloidosis report encloses the detailed analysis of AL amyloidosis early-stage (Phase-I/II, II, and III) pipeline drugs. It also helps to understand the AL Amyloidosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
The AL amyloidosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted AL amyloidosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand of better technology.
This segment gives a thorough detail of AL Amyloidosis market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the AL Amyloidosis market in 7MM is expected to grow during the study period 2017–2030.
High-dose melphalan followed by ASCT is one treatment option included in the National Comprehensive Cancer Network guidelines. Induction with high-dose melphalan followed by ASCT has significantly impacted the ability to achieve a deep hematological response, organ response, and improved survival in patients eligible for this procedure. In recent years, bortezomib-based regimens were more frequently used as a pre-ASCT induction and increased survival. This treatment method is associated with significant side morbidity and mortality; therefore, only about 20–30% of patients are eligible. The PFS by period among the ASCT-treated patients was in the range of 53 months and giving survival for more than 2 years. HSCT and its associated complications are costly, depending on patient characteristics, transplant center experience, graft type, hospitalization duration, and transplantation complications. Further, hematological relapses or progression after ASCT occurs in 36–38% of patients at a median of 2.0–4.3 years after treatment.
Among the ineligible ASCT patients, the inflection point seems to have occurred around 2005, with incremental PFS or OS benefit observed in the most recent era, with the introduction of melphalan, in combination with dexamethasone (MDex) as a substitute for melphalan and prednisone (MP). This change had a profound impact on patient survival and the treatment pattern.
This section includes a glimpse of the AL amyloidosis market in 7MM. The market size of AL Amyloidosis in the seven major markets was found to be USD 887.3 Million in 2017.
The United States Market Outlook
This section provides the total AL Amyloidosis market size and market size by therapies in the United States.
DelveInsight estimates show that the United States accounted for the highest market size compared to EU5 and Japan.
EU-5 Countries: Market Outlook
The total AL Amyloidosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The totals AL Amyloidosis market Size and market Size by therapies in Japan are also mentioned.
This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers the AL amyloidosis market uptake by drugs, patient uptake by therapies, and drug sales.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
AL Amyloidosis Pipeline Development Activities
The report provides insights into the therapeutic candidate in phase I/II, II, and III stages. It also analyses AL Amyloidosis key players involved in developing targeted therapeutics.
Major players include Janssen Pharmaceuticals, Caelum Biosciences, Oncopeptides AB, and Bristol Myers Squibb.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisitions and mergers, licensing, and patent details for AL Amyloidosis emerging therapies.
Proactively approaching reimbursement can induce a positive impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Clinical practice guidelines by NCCN, UKMF provided a list of drug therapy options for AL Amyloidosis; however, none had FDA or EMA approval. This treatment landscape of AL amyloidosis is mostly derived from multiple myeloma, and none are deemed optimal due to insufficient data. High-dose melphalan followed by autologous hematopoietic stem cell transplant (ASCT) is included in the guidelines, but it is associated with significant morbidity and mortality; therefore, only about 20% of patients are eligible. Transplantation improved life expectancy, and one of the Canadian-based studies extrapolated survival and costs of the ASCT with melphalan and prednisone group. The incremental cost-effectiveness of transplantation was 25,710 Canadian dollars per life-year gained, including follow-up costs. Compared with melphalan and prednisone, ASCT appears to be cost-effective in patients less than 65 years old.
To keep up with current market trends, we take KOLs and SME’s opinion working in the AL amyloidosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or AL Amyloidosis market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.
We perform Competitive and Market Intelligence analysis of the AL Amyloidosis Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
AL Amyloidosis Report Insights
AL Amyloidosis Report Key Strengths
AL Amyloidosis Report Assessment
Market Insights:
Epidemiology Insights:
1. Key Insights
2. Executive Summary of AL Amyloidosis
3. Competitive Intelligence Analysis for AL Amyloidosis
4. AL Amyloidosis: Market Overview at a Glance
4.1. AL Amyloidosis Total Market Share (%) Distribution in 2017
4.2. AL Amyloidosis Total Market Share (%) Distribution in 2030
5. AL Amyloidosis: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. AL Amyloidosis Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. AL Amyloidosis Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. AL Amyloidosis Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. AL Amyloidosis Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. AL Amyloidosis Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. AL Amyloidosis Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. AL Amyloidosis Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. AL Amyloidosis Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. AL Amyloidosis Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. AL Amyloidosis Treatment and Management
8.2. AL Amyloidosis Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of AL Amyloidosis Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. AL Amyloidosis: Seven Major Market Analysis
13.1. Key Findings
13.2. AL Amyloidosis Market Size in 7MM
13.3. AL Amyloidosis Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. AL Amyloidosis Total Market Size in the United States
15.1.2. AL Amyloidosis Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. AL Amyloidosis Total Market Size in Germany
15.3.2. AL Amyloidosis Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. AL Amyloidosis Total Market Size in France
15.4.2. AL Amyloidosis Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. AL Amyloidosis Total Market Size in Italy
15.5.2. AL Amyloidosis Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. AL Amyloidosis Total Market Size in Spain
15.6.2. AL Amyloidosis Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. AL Amyloidosis Total Market Size in the United Kingdom
15.7.2. AL Amyloidosis Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. AL Amyloidosis Total Market Size in Japan
15.8.3. AL Amyloidosis Market Size by Therapies in Japan
16. Access and Reimbursement Overview of AL Amyloidosis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
List of Tables
Table 1 : 7MM AL Amyloidosis Epidemiology (2017-2030)
Table 2 : 7MM AL Amyloidosis Diagnosed and Treatable Cases (2017-2030)
Table 3 : Disease% Epidemiology in the United States (2017-2030)
Table 4 : AL Amyloidosis Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 : AL Amyloidosis Epidemiology in Germany (2017-2030)
Table 6 : AL Amyloidosis Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 : AL Amyloidosis Epidemiology in France (2017-2030)
Table 8 : AL Amyloidosis Diagnosed and Treatable Cases in France (2017-2030)
Table 9 : AL Amyloidosis Epidemiology in Italy (2017-2030)
Table 10 : AL Amyloidosis Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 : AL Amyloidosis Epidemiology in Spain (2017-2030)
Table 12 : AL Amyloidosis Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 : AL Amyloidosis Epidemiology in the UK (2017-2030)
Table 14 : AL Amyloidosis Diagnosed and Treatable Cases in the UK (2017-2030)
Table 15 : AL Amyloidosis Epidemiology in Japan (2017-2030)
Table 16 : AL Amyloidosis Diagnosed and Treatable Cases in Japan (2017-2030)
Table 17 : Drug Name, Clinical Trials by Recruitment status
Table 18 : Drug Name, Clinical Trials by Zone
Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
Table 20 : Region-wise Market Size in USD, Million (2017-2030)
Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
Table 22 : United States Market Size in USD, Million (2017-2030)
Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
Table 24 : Germany Market Size in USD, Million (2017-2030)
Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
Table 26 : France Market Size in USD, Million (2017-2030)
Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
Table 28 : Italy Market Size in USD, Million (2017-2030)
Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
Table 30 : Spain Market Size in USD, Million (2017-2030)
Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
Table 34 : Japan Market Size in USD, Million (2017-2030)
Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)
List of Figures
Figure 1 : 7MM AL Amyloidosis Epidemiology (2017-2030)
Figure 2 : 7MM AL Amyloidosis Diagnosed and Treatable Cases (2017-2030)
Figure 3 : AL Amyloidosis Epidemiology in the United States (2017-2030)
Figure 4 : AL Amyloidosis Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 : AL Amyloidosis Epidemiology in Germany (2017-2030)
Figure 6 : AL Amyloidosis Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 : AL Amyloidosis Epidemiology in France (2017-2030)
Figure 8 : AL Amyloidosis Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 : AL Amyloidosis Epidemiology in Italy (2017-2030)
Figure 10 : AL Amyloidosis Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 : AL Amyloidosis Epidemiology in Spain (2017-2030)
Figure 12 : AL Amyloidosis Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 : AL Amyloidosis Epidemiology in the UK (2017-2030)
Figure 14 : AL Amyloidosis Diagnosed and Treatable Cases in the UK (2017-2030)
Figure 15 : AL Amyloidosis Epidemiology in Japan (2017-2030)
Figure 16 : AL Amyloidosis Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 17 : Drug Name, Clinical Trials by Recruitment status
Figure 18 : Drug Name, Clinical Trials by Zone
Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
Figure 22 : United States Market Size in USD, Million (2017-2030)
Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
Figure 24 : Germany Market Size in USD, Million (2017-2030)
Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
Figure 26 : France Market Size in USD, Million (2017-2030)
Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
Figure 28 : Italy Market Size in USD, Million (2017-2030)
Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
Figure 30 : Spain Market Size in USD, Million (2017-2030)
Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
Figure 34 : Japan Market Size in USD, Million (2017-2030)
Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)
Janssen Pharmaceutical
Caelum Biosciences
Oncopeptides AB
Bristol-Myers Squibb
Acrotech biopharma
Sanofi
